|
[1]
|
Bullock, J., Rizvi, S., Saleh, A.M., et al. (2018) Rheumatoid Arthritis: A Brief Overview of the Treatment. Medical Principles and Practice, 27, 501-507. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Littlejohn, E.A. and Monrad, S.U. (2018) Early Diagnosis and Treatment of Rheumatoid Arthritis. Primary Care, 45, 237-255. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Lin, Y.J., Anzaghe, M. and Schülke, S. (2020) Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells, 9, 880. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Blum, A. and Adawi, M. (2019) Rheumatoid Arthritis (RA) and Car-diovascular Disease. Autoimmunity Reviews, 18, 679-690. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Semb, A.G., Ikdahl, E., Wibetoe, G., et al. (2020) Atherosclerotic Cardiovascular Disease Prevention in Rheumatoid Arthritis. Nature Reviews Rheumatology, 16, 361-379. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Li, H., Sun, K., Zhao, R., et al. (2018) Inflammatory Biomarkers of Coronary Heart Disease. Frontiers in Bioscience (Schol Ed), 10, 185-196. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Løgstrup, B.B., Olesen, K., Masic, D., et al. (2020) Impact of Rheumatoid Ar-thritis on Major Cardiovascular Events in Patients with and without Coronary Artery Disease. Annals of Rheumatic Diseases, 79, 1182-1188. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Aviña-Zubieta, J.A., Choi, H.K., Sadatsafavi, M., et al. (2008) Risk of Cardiovascular Mortality in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies. Arthritis & Rheumatology, 59, 1690-1697. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Humphreys, J.H., Warner, A., Chipping, J., et al. (2014) Mortality Trends in Patients with Early Rheumatoid Arthritis over 20 Years: Results from the Norfolk Arthritis Register. Arthritis Care & Research (Hoboken), 66, 1296-1301. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Aubry, M.C., Maradit-Kremers, H., Reinalda, M.S., et al. (2007) Differ-ences in Atherosclerotic Coronary Heart Disease between Subjects with and without Rheumatoid Arthritis. The Journal of Rheumatology, 34, 937-942.
|
|
[11]
|
Dalbeni, A., Giollo, A., Bevilacqua, M., et al. (2020) Traditional Cardiovascular Risk Factors and Residual Disease Activity Are Associated with Atherosclerosis Progression in Rheumatoid Arthritis Patients. Hypertension Research, 43, 922-928. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Chung, C.P., Oeser, A., Raggi, P., et al. (2005) Increased Coronary-Artery Atherosclerosis in Rheumatoid Arthritis: Relationship to Disease Duration and Cardiovascular Risk Factors. Arthritis & Rheumatology, 52, 3045-3053. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Quevedo-Abeledo, J.C., Rúa-Figueroa, Í., Sánchez-Pérez, H., et al. (2020) Comparable Effects of Traditional Cardiovascular Risk Factors on Subclinical Atherosclerosis in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 38, 917-924.
|
|
[14]
|
Tektonidou, M.G., Kravvariti, E., Konstantonis, G., et al. (2017) Subclinical Atherosclerosis in Systemic Lupus Erythematosus: Comparable Risk with Diabetes Mellitus and Rheumatoid Arthritis. Autoimmunity Reviews, 16, 308-312. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Crowson, C.S., Gabriel, S.E., Semb, A.G., et al. (2017) Rheu-matoid Arthritis-Specific Cardiovascular Risk Scores Are Not Superior to General Risk Scores: A Validation Analysis of Patients from Seven Countries. Rheumatology (Oxford), 56, 1102-1110. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Kumar, N. and Armstrong, D.J. (2008) Cardiovascular Dis-ease—The Silent Killer in Rheumatoid Arthritis. Clinical Medicine (London), 8, 384-387. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Wang, H., Li, X. and Gong, G. (2020) Cardiovascular Outcomes in Patients with Co-Existing Coronary Artery Disease and Rheumatoid Arthritis: A Systematic Review and Me-ta-Analysis. Medicine (Baltimore), 99, e19658. [Google Scholar] [CrossRef]
|
|
[18]
|
Ridker, P.M., Rifai, N., Stampfer, M.J., et al. (2000) Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction among Apparently Healthy Men. Circulation, 101, 1767-1772. [Google Scholar] [CrossRef]
|
|
[19]
|
Guerra, J.D., De Santiago, A.B., Reed, S., et al. (2022) Cardi-ology Co-Management of Rheumatoid Arthritis Patients with Coronary Artery Disease as an Intervention Reduces Hospitalization Rates and Adverse Event Occurrence. Clinical Rheumatology, 41, 3715-3724. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Jagpal, A. and Navarro-Millán, I. (2018) Cardiovascular Co-Morbidity in Patients with Rheumatoid Arthritis: A Narrative Review of Risk Factors, Cardiovascular Risk As-sessment and Treatment. BMC Rheumatology, 2, 10. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Hannawi, S., Hannawi, H. and Al, S.I. (2020) Cardiovascular Disease and Subclinical Atherosclerosis in Rheumatoid Arthritis. Hypertension Research, 43, 982-984. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Liao, K.P. (2017) Cardiovascular Disease in Patients with Rheumatoid Arthritis. Trends in Cardiovascular Medicine, 27, 136-140. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Reiss, A.B., Silverman, A., Khalfan, M., et al. (2019) Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment. Current Pharmaceutical Design, 25, 969-986. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Adawi, M., Firas, S. and Blum, A. (2019) Rheumatoid Arthritis and Atherosclerosis. The Israel Medical Association Journal, 21, 460-463.
|
|
[25]
|
Halacoglu, J. and Shea, L.A. (2020) Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis. Journal of Cardi-ovascular Translational Research, 13, 878-890. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
England, B.R., Thiele, G.M. anderson, D.R., et al. (2018) In-creased Cardiovascular Risk in Rheumatoid Arthritis: Mechanisms and Implications. BMJ, 361, k1036. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Tanrıkulu, O., Sarıyıldız, M.A., Batmaz, O., et al. (2017) Serum GDF-15 Level in Rheumatoid Arthritis: Relationship with Disease Activity and Subclinical Atherosclerosis. Acta Reumatologica Portuguesa, 42, 66-72.
|
|
[28]
|
Jones, S.A. (2005) Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6. The Journal of Immunology, 175, 3463-3468. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Kahlenberg, J.M. and Kaplan, M.J. (2013) Mechanisms of Premature Atherosclerosis in Rheumatoid Arthritis and Lupus. Annual Review of Medicine, 64, 249-263. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Striz, I. (2017) Cytokines of the IL-1 Family: Recog-nized Targets in Chronic Inflammation Underrated in Organ Transplantations. Clinical Science (London), 131, 2241-2256. [Google Scholar] [CrossRef]
|
|
[31]
|
Robertson, A.K. and Hansson, G.K. (2006) T Cells in Atherogenesis: For Better or for Worse? Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2421-2432. [Google Scholar] [CrossRef]
|
|
[32]
|
Buono, C., Pang, H., Uchida, Y., et al. (2004) B7-1/B7-2 Costimulation Regulates Plaque Antigen-Specific T-Cell Responses and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. Circulation, 109, 2009-2015. [Google Scholar] [CrossRef]
|
|
[33]
|
Zeisbrich, M., Yanes, R.E., Zhang, H., et al. (2018) Hypermetabolic Macrophages in Rheumatoid Arthritis and Coronary Artery Disease Due to Glycogen Synthase Kinase 3b Inactivation. Annals of Rheumatic Diseases, 77, 1053-1062. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
杨金娜, 刘晓光, 李覃, 等. Th17/Treg平衡在类风湿关节炎中作用的研究进展[J]. 中国药理学通报, 2013, 29(8): 1045-1048.
|
|
[35]
|
Wahlin, B., Fasth, A., Karp, K., et al. (2021) Atherosclerosis in Rheumatoid Arthritis: Associations between Anti-Cytomegalovirus IgG Antibodies, CD4+CD28null T-Cells, CD8+CD28null T-Cells and Intima-Media Thickness. Clinical and Experimental Rheumatology, 39, 578-586. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Kisiel, B., Kruszewski, R., Juszkiewicz, A., et al. (2019) Common Atherosclerosis Genetic Risk Factors and Subclinical Atherosclerosis in Rheumatoid Arthritis: The Relevance of Disease Duration. Rheumatology International, 39, 327-336. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Sokolove, J., Brennan, M.J., Sharpe, O., et al. (2013) Brief Re-port: Citrullination within the Atherosclerotic Plaque: A Potential Target for the Anti-Citrullinated Protein Antibody Response in Rheumatoid Arthritis. Arthritis & Rheumatology, 65, 1719-1724. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Brink, M., Hansson, M., Mathsson-Alm, L., et al. (2016) Rheumatoid Factor Isotypes in Relation to Antibodies against Citrullinated Peptides and Carbamylated Proteins before the Onset of Rheumatoid Arthritis. Arthritis Research & Therapy, 18, 43. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Hejblum, B.P., Cui, J., Lahey, L.J., et al. (2018) Association between Anti-Citrullinated Fibrinogen Antibodies and Coronary Artery Disease in Rheumatoid Arthritis. Arthritis Care & Research (Hoboken), 70, 1113-1117. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
史俊, 季晨, 雷鑫, 等. 类风湿关节炎合并冠状动脉粥样硬化性心脏病的研究进展[J]. 新医学, 2020, 51(7): 506-511.
|
|
[41]
|
Braz, N., Pinto, M., Vieira, É., et al. (2021) Renin-Angiotensin System Molecules Are Associated with Subclinical Atherosclerosis and Disease Activity in Rheumatoid Arthritis. Modern Rheumatology, 31, 119-126. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Fragoulis, G.E., Panayotidis, I. and Nikiphorou, E. (2020) Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment. Current Vascular Pharmacology, 18, 431-446. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Ormseth, M.J., Solus, J.F., Sheng, Q., et al. (2021) Plasma miRNAs Improve the Prediction of Coronary Atherosclerosis in Patients with Rheumatoid Arthritis. Clinical Rheumatology, 40, 2211-2219. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Foinquinos, A., Batkai, S., Genschel, C., et al. (2020) Preclinical Development of a miR-132 Inhibitor for Heart Failure Treatment. Nature Communications, 11, 633. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Tanase, D.M., Gosav, E.M., Petrov, D., et al. (2022) MicroRNAs (miRNAs) in Cardiovascular Complications of Rheumatoid Arthritis (RA): What Is New? International Journal of Molecular Sciences, 23, 5254. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Ormseth, M.J., Solus, J.F., Vickers, K.C., et al. (2015) Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis. The Journal of Rheumatology, 42, 1746-1751. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Barbhaiya, M. and Solomon, D.H. (2013) Rheumatoid Arthritis and Cardiovascular Disease: An Update on Treatment Issues. Current Opinion in Rheumatology, 25, 317-324. [Google Scholar] [CrossRef]
|
|
[48]
|
Giollo, A., Bissell, L.A. and Buch, M.H. (2018) Cardio-vascular Outcomes of Patients with Rheumatoid Arthritis Prescribed Disease Modifying Anti-Rheumatic Drugs: A Re-view. Expert Opinion on Drug Safety, 17, 697-708. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Ocon, A.J., Reed, G., Pappas, D.A., et al. (2021) Short-Term Dose and Duration-Dependent Glucocorticoid Risk for Cardiovascular Events in Glucocorticoid-Naive Pa-tients with Rheumatoid Arthritis. Annals of Rheumatic Diseases, 80, 1522-1529. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Wang, Y., Su, R., Li, B., et al. (2021) Reduction of Pe-ripheral Regulatory T Cells in Active Rheumatoid Arthritis Patients with Coronary Artery Disease. BMC Immunology, 22, 76. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Boers, M., Nurmohamed, M.T., Doelman, C.J., et al. (2003) Influence of Glucocorticoids and Disease Activity on Total and High Density Lipoprotein Cholesterol in Patients with Rheumatoid Arthritis. Annals of Rheumatic Diseases, 62, 842-845. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Kisiel, B., Kruszewski, R., Juszkiewicz, A., et al. (2015) Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. Journal of Immunology Research, 2015, Article ID: 759610. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Verhoeven, F., Prati, C., Chouk, M., et al. (2021) Methotrexate and Cardiovascular Risk in Rheumatic Diseases: A Comprehensive Review. Expert Review of Clinical Pharmacology, 14, 1105-1112. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Ikonomidis, I., Tzortzis, S. andreadou, I., et al. (2014) In-creased Benefit of Interleukin-1 Inhibition on Vascular Function, Myocardial Deformation, and Twisting in Patients with Coronary Artery Disease and Coexisting Rheumatoid Arthritis. Circulation: Cardiovascular Imaging, 7, 619-628. [Google Scholar] [CrossRef]
|
|
[55]
|
Ljung, L., Askling, J., Rantapää-Dahlqvist, S., et al. (2014) The Risk of Acute Coronary Syndrome in Rheumatoid Arthritis in Relation to Tumour Necrosis Factor Inhibitors and the Risk in the General Population: A National Cohort Study. Arthritis Research & Therapy, 16, R127. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Toussirot, É. (2015) Effects of TNFα Inhibitors on Adiposity and Other Car-diovascular Risk Factors: Implications for the Cardiovascular Prognosis in Patients with Rheumatoid Arthritis. Expert Opinion on Drug Safety, 14, 525-532. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Kaur, K., Kalra, S. and Kaushal, S. (2014) Systematic Re-view of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis. Clinical Therapeutics, 36, 1074-1086. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Kremer, J.M. (2021) Methotrexate and Cardiovascular Disease in Patients with Rheumatoid Arthritis: Insights and Novel Speculations. The Journal of Rheumatology, 48, 793-795. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
白景芝, 刘永杰. IL-6、RF、ACCP及凝血指标在冠心病合并类风湿关节炎患者中的表达及意义[J]. 中国卫生工程学, 2020, 19(3): 459-461.
|